Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 189 participants.

Also called NCT07586865

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 189 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07586865
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07586865. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-18 (anticipated); primary completion 2027-08-17 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
Condition
Acute Myocardial Infarction (AMI)
Condition
Acute Myocardial Infarction of Anterior Wall
Condition
Acute Myocardial Infarction With ST Elevation
Condition
Acute Myocardial Infarction of Left Ventricle
Condition
Acute Myocardial Infarction With ST Segment Elevation
Intervention (Drug)
Recombinant Human Thymosin Beta 4 Injection (NL005)
Intervention (Drug)
Placebo
Lead sponsor
Beijing Northland Biotech. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07586865
Content hash
b903c2c43f625fe8f4d53158e31fa542c329e9df58f3bd465ba804f8c956c9a5